BLASUBCUTANEOUSSOLUTION
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
RITUXAN HYCELA (rituximab and hyaluronidase) by Roche is cd20-directed antibody interactions [moa]. Approved for endoglycosidase [epc]. First approved in 2017.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITUXAN HYCELA is a subcutaneous formulation combining rituximab (a CD20-directed monoclonal antibody) with hyaluronidase, enabling subcutaneous delivery of this established B-cell lymphoma and autoimmune therapy. The hyaluronidase enzyme facilitates subcutaneous administration by temporarily breaking down hyaluronic acid in subcutaneous tissue, improving drug distribution and patient convenience. This formulation maintains the well-established anti-CD20 mechanism while eliminating the need for intravenous infusion.
$0.638MPart D
PeakProduct is in peak lifecycle phase, indicating mature commercialization with stable team structure and focus on market defense rather than aggressive expansion.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Started Apr 2021
3 enrolled
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular Lymphoma+11 more
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Started Jun 2019
15 enrolled
Cutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVStage III Melanoma+5 more
Worked on RITUXAN HYCELA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.